Close Menu

NEW YORK – Results from a new analysis suggest women carrying risky BRCA1 or BRCA2 mutations who are diagnosed with breast cancer may be less apt to receive cancer treatment dictated by current practice guidelines than BRCA mutation-free breast cancer patients.

"We need to understand this gap better, because it could have potential implications on patients' outcomes," senior author Steven Katz, a general medicine, and health management and policy researcher affiliated with the University of Michigan and Stanford University, said in a statement.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.